Abstract：
BACKGROUND: The neuroprotective effects of Dehydroepiandrosterone (DHEA) and Hericium erinaceus (H. erinaceus) mushroom extract against scopolamine-induced Alzheimer\'s disease-like symptoms in male Wistar rats were investigated.
METHODS: Sixty-four male Wistar rats were divided into eight groups (n = 8). Scopolamine (SCO) was intraperitoneally injected at a dose of 1 mg/kg/day for 10 days. The treatment groups orally received DHEA (250 mg/kg/day) and/or H. erinaceus (300 mg/kg/day) for 14 days. Afterward, the Morris water maze (MWM) and novel object recognition tests were implemented. Then, animals were anesthetized and the brain tissue samples were separated. Levels of lipid peroxidation (LPO), total antioxidant capacity (TAC), catalase activity (CAT), and brain-derived neurotrophic factor (BDNF) were determined. Also, histopathological studies were evaluated in the brain tissue samples.
RESULTS: Administration of SCO significantly decreased spatial and cognitive memory (p < 0.001). Not only did SCO injection significantly increase the levels of the LPO but also the SCO markedly reduced the levels of the TAC, CAT activity, and the BDNF in the brain tissue. On the other hand, a combination of the DHEA and H. erinaceus showed higher efficacy than the DHEA or H. erinaceus in attenuating behavioral anomalies and improving the antioxidant defense system and BDNF levels. Histological examination was well correlated with biochemical findings regarding SCO neurodegeneration and DHEA and/or H. erinaceus neuroprotection.
CONCLUSIONS: Interestingly, ADHE and/or H. erinaceus may due to their potential neurotrophic properties be used as a new and beneficial concurrent therapy in the treatment of Alzheimer\'s disease-like symptoms caused by SCO.
METHODS: Sixty-four male Wistar rats were divided into eight groups (n = 8). Scopolamine (SCO) was intraperitoneally injected at a dose of 1 mg/kg/day for 10 days. The treatment groups orally received DHEA (250 mg/kg/day) and/or H. erinaceus (300 mg/kg/day) for 14 days. Afterward, the Morris water maze (MWM) and novel object recognition tests were implemented. Then, animals were anesthetized and the brain tissue samples were separated. Levels of lipid peroxidation (LPO), total antioxidant capacity (TAC), catalase activity (CAT), and brain-derived neurotrophic factor (BDNF) were determined. Also, histopathological studies were evaluated in the brain tissue samples.
RESULTS: Administration of SCO significantly decreased spatial and cognitive memory (p < 0.001). Not only did SCO injection significantly increase the levels of the LPO but also the SCO markedly reduced the levels of the TAC, CAT activity, and the BDNF in the brain tissue. On the other hand, a combination of the DHEA and H. erinaceus showed higher efficacy than the DHEA or H. erinaceus in attenuating behavioral anomalies and improving the antioxidant defense system and BDNF levels. Histological examination was well correlated with biochemical findings regarding SCO neurodegeneration and DHEA and/or H. erinaceus neuroprotection.
CONCLUSIONS: Interestingly, ADHE and/or H. erinaceus may due to their potential neurotrophic properties be used as a new and beneficial concurrent therapy in the treatment of Alzheimer\'s disease-like symptoms caused by SCO.
摘要：
背景：脱氢表雄酮（DHEA）和猴头菌的神经保护作用（H。在雄性Wistar大鼠中，研究了香菇提取物对东莨菪碱诱导的阿尔茨海默病样症状的影响。
方法：64只雄性Wistar大鼠分为8组(n=8)。以1mg/kg/天的剂量腹膜内注射东莨菪碱(SCO),持续10天。治疗组经口接受DHEA(250mg/kg/天)和/或紫苏杆菌(300mg/kg/天)14天。之后,Morris水迷宫（MWM）和新的目标识别测试。然后，将动物麻醉并分离脑组织样品。脂质过氧化（LPO）的水平，总抗氧化能力(TAC)，过氧化氢酶活性（CAT），测定脑源性神经营养因子(BDNF)。此外，在脑组织样本中评估了组织病理学研究。
结果：给予SCO显著降低空间和认知记忆（p<0.001）。SCO注入不仅显著增加了LPO的水平，而且SCO显著降低了TAC的水平，CAT活动,和脑组织中的BDNF。另一方面,在减轻行为异常和改善抗氧化防御系统和BDNF水平方面，DHEA和H.erinaceus的组合显示出比DHEA或H.erinaceus更高的功效。组织学检查与有关SCO神经变性和DHEA和/或H.erinaceus神经保护的生化发现密切相关。
结论：有趣的是，由于其潜在的神经营养特性，ADHE和/或马氏真菌可能被用作一种新的有益的同步治疗，用于治疗由SCO引起的阿尔茨海默病样症状。
方法：64只雄性Wistar大鼠分为8组(n=8)。以1mg/kg/天的剂量腹膜内注射东莨菪碱(SCO),持续10天。治疗组经口接受DHEA(250mg/kg/天)和/或紫苏杆菌(300mg/kg/天)14天。之后,Morris水迷宫（MWM）和新的目标识别测试。然后，将动物麻醉并分离脑组织样品。脂质过氧化（LPO）的水平，总抗氧化能力(TAC)，过氧化氢酶活性（CAT），测定脑源性神经营养因子(BDNF)。此外，在脑组织样本中评估了组织病理学研究。
结果：给予SCO显著降低空间和认知记忆（p<0.001）。SCO注入不仅显著增加了LPO的水平，而且SCO显著降低了TAC的水平，CAT活动,和脑组织中的BDNF。另一方面,在减轻行为异常和改善抗氧化防御系统和BDNF水平方面，DHEA和H.erinaceus的组合显示出比DHEA或H.erinaceus更高的功效。组织学检查与有关SCO神经变性和DHEA和/或H.erinaceus神经保护的生化发现密切相关。
结论：有趣的是，由于其潜在的神经营养特性，ADHE和/或马氏真菌可能被用作一种新的有益的同步治疗，用于治疗由SCO引起的阿尔茨海默病样症状。
